TITLE:

AUTHOR(S):
Ishikawa, Yuki; Yukawa, Naoichiro; Ohmura, Koichiro; Hosono, Yuji; Imura, Yoshitaka; Kawabata, Daisuke; Nojima, Takaki; Fujii, Takao; Usui, Takashi; Mimori, Tsuneyo

CITATION:

ISSUE DATE:
2010-05

URL:
http://hdl.handle.net/2433/120949

RIGHT:
The original publication is available at www.springerlink.com; This is not the published version. Please cite only the published version.; この論文は出版社版ではありません。引用の際には出版社版をご確認ご利用ください。
---|---|---|---|---|---
Age (yrs) & Sex | 44 female | 52 female | 52 female | 57 female | 58 female
RF/CCP | -/- | +/ND<sup>1</sup> | +/ND | +/ND | *(724.7)/+ (> 100)<sup>1</sup>
Duration from RA until anti-TNF therapy (Tx.) initiation (yrs) | 1 | 20 | 33 | 26 | 2
Previous Tx. for RA | HCQ<sup>2</sup>, MTX<sup>3</sup> | MTX | MTX | All available DMARDs | BUC<sup>4</sup>, TAC<sup>5</sup>
Anti-TNF therapy | Etanercept | Infliximab | Infliximab | Etanercept | Etanercept
PM/DM onset from anti-TNF Tx. initiation | 6 months | 6 months | 9 months | 6 wks after re-treatment | 2 months
Maximum CK<sup>6</sup> (IU/L) | 11,593 | > 12,000 | 3,388 | 1,067 | 1,538
pre FANA | – | 1:320, pattern unknown | 1:640, Ho./Spe.<sup>8</sup> | 1:160 (1999) | 1:320, Ho./Nucl.<sup>8</sup>
Pre<sup>10</sup> anti-dsDNA antibody | ND | – | – | ND | –
Anti-dsDNA antibody | ND | 1:20 | IgM (131 U/mL) | ND | – (IgG 11 U/mL)
Pre Anti-Jo-1 antibody | ND | + | + (> 500 U/mL) (ELISA) | ND | 206.9
Anti-Jo-1 antibody | + | + | + (> 500 U/mL) (ELISA) | ND | 239
Electromyogram | ND | ND | ND | Myogenic pattern | Myogenic pattern
Muscle biopsy | Necrosis, perivascular interstitial infiltration | Diffuse necrosis, inflammatory infiltrates | Size variation, inflammatory infiltrates | Necrotizing myositis | Mild inflammatory infiltrates and necrosis
Diagnosis | Dermatomyositis | Polymyositis | Polymyositis | Polymyositis | Polymyositis
Course & types of ILD | Improved; NSIP<sup>11</sup> ? | Improved; UIP<sup>12</sup> ? | Improved; NSIP ? | ARDS developed, due to PCP<sup>11</sup> ? | Improved; NSIP or BOOP<sup>14</sup>
Tx. for PM/DM<sup>15</sup> | High-dose PSL<sup>16</sup> plus AZP<sup>16</sup> 17 150 mg & MTX 10 mg/wk | MP<sup>18</sup> pulse 1.0 g plus PSL 1 mg/kg | PSL 30 mg plus TAC 3 mg | High-dose PSL plus IVCY<sup>19</sup> (500 mg/m<sup>2</sup>) | PSL 1 mg/kg plus MP pulse 0.5 g
Outcome of myositis | Marked improvement | Marked improvement | Marked improvement | Marked improvement | Marked improvement

Table 1. Clinical Characteristics of Reported RA Patients Who Developed PM/DM After Anti-TNF Therapy

<sup>1</sup> ND Not done or Not described  
<sup>2</sup> HCQ hydroxychloroquine  
<sup>3</sup> MTX methotrexate  
<sup>4</sup> BUC bucillamine  
<sup>5</sup> TAC tacrolimus  
<sup>6</sup> CPK creatinine phosphokinase  
<sup>7</sup> Ho. Homogenous pattern  
<sup>8</sup> Spe. Speckled pattern  
<sup>9</sup> Nucl. Nucleolar pattern  
<sup>10</sup> pre value before initiation of anti-TNF  
<sup>11</sup> NSIP non-specific interstitial pneumonia  
<sup>12</sup> UIP unusual interstitial pneumonia  
<sup>13</sup> PCP pneumocystis pneumonia  
<sup>14</sup> BOOP bronchiolitis obliterans with organizing pneumonia  
<sup>15</sup> All treatment include withdraw of anti-TNF therapy  
<sup>16</sup> PSL prednisolone  
<sup>17</sup> AZP azathioprine  
<sup>18</sup> MP methylprednisolone  
<sup>19</sup> IVCY intravenous cyclophosphamide